TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12847369

Group type: EXPERIMENTAL
Intervention: Direct end‐to‐end repair
Number of subjects: 23

Group type: COMPARATOR
Intervention: Overlapping sphincter repair
Number of subjects: 23
Study: 10596247

Group type: EXPERIMENTAL
Intervention: Behavioral Family Systems Therapy (BFST)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Ego‐Oriented Individual Therapy (EOIT)
Number of subjects: 37
Study: 8695600

Group type: EXPERIMENTAL
Intervention: Resistant starch from potato (17-30 g/d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Resistant starch from banana (17-30 g/d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Resistant starch from wheat (17-30 g/d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Resistant starch from maize (17-30 g/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bran NSP (18.4 g NSP from bran/d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All forms of resistant starch
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: RS2 (from potato and banana)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: RS3 (from wheat and maize)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Resistant starch
Number of subjects: 12
Study: 1917046

Group type: EXPERIMENTAL
Intervention: Intravenous penicillin G sodium (PG) 400,000‐500,000 I.U./kg/day for 14 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: Intravenous ceftriaxone 75‐93 mg/kg/day for 14 days
Number of subjects: 23
Study: 6627213

Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Adriamycin combinations
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cycloleucine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Bleomycin
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Non-Adriamycin combinations
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Crossover therapy (Adriamycin)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Adriamycin treated patients
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Nonresponders
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Entire series
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Patients with abdominal mesothelioma
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: South African patients
Number of subjects: 96
Study: 30959882

Group type: EXPERIMENTAL
Intervention: Repetitive screwing task on day 1
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Repetitive screwing task on day 2
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Repetitive screwing task (extensor digitorum and biceps brachii)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Repetitive screwing task (flexor carpi radialis and triceps brachii)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Repetitive screwing task
Number of subjects: 57
Study: 29920736

Group type: EXPERIMENTAL
Intervention: Mirogabalin 15 mg + Probenecid 500 mg every 6 h from days 1 to 4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirogabalin 15 mg + Cimetidine 400 mg every 6 h from days 1 to 4
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mirogabalin 15 mg alone
Number of subjects: 0
Study: 27422406

Group type: EXPERIMENTAL
Intervention: CFNB/SAMO group (continuous femoral nerve block with mini-dose spinal morphine)
Number of subjects: 68

Group type: COMPARATOR
Intervention: CFNB/SA group (continuous femoral nerve block with spinal anesthesia)
Number of subjects: 68
Study: 24814858

Group type: EXPERIMENTAL
Intervention: Folic acid (5mg daily) and vitamin B12 (500 μg twice daily) for 12 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Non-intervention (control group)
Number of subjects: 72
Study: 22574583

Group type: EXPERIMENTAL
Intervention: QSDCMM combined with rehabilitation training
Number of subjects: 90

Group type: COMPARATOR
Intervention: Western medicine treatment group (Chinese medicine placebo, Western medicine, and rehabilitation)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (Chinese medicine placebo and rehabilitation)
Number of subjects: 90
Study: 21344827

Group type: EXPERIMENTAL
Intervention: Oral-B Pulsonic sonic toothbrush
Number of subjects: 129

Group type: COMPARATOR
Intervention: ADA reference manual toothbrush
Number of subjects: 129
Study: 17913672

Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 119
Study: 16061122

Group type: EXPERIMENTAL
Intervention: Patients with PAD (ABI<0.9)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls (ABI>1)
Number of subjects: 0
Study: 11777104

Group type: EXPERIMENTAL
Intervention: High-standardization CBT
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Low-standardization CBT
Number of subjects: 252

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: All conditions (High-standardization CBT, Low-standardization CBT, Treatment as usual)
Number of subjects: 252
Study: 9610341

Group type: EXPERIMENTAL
Intervention: Iloprost low dose (LD) 100 micrograms bid for 8 weeks
Number of subjects: 319

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Iloprost high dose (HD) 200 micrograms bid for 8 weeks
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Iloprost low dose (LD) and high dose (HD)
Number of subjects: 319
Study: 7923253

Group type: EXPERIMENTAL
Intervention: rt-PA administered within 6 to 24 hours after onset of symptoms
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no thrombolytic agent)
Number of subjects: 100
Study: 3288479

Group type: EXPERIMENTAL
Intervention: Low-dose bromocriptine
Number of subjects: 128

Group type: COMPARATOR
Intervention: L-dopa
Number of subjects: 128
Study: 4627050

Group type: EXPERIMENTAL
Intervention: Continuous intragastric milk feeds (60 ml/kg/24 hr to 300 ml/kg/24 hr over 9 days) using either expressed human breast milk or SMA-S26.
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: SMA-S26 (a proprietary low-protein adapted cows' milk)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Half-cream Regal milk (partly-skimmed evaporated cows' milk)
Number of subjects: 66
Study: 30838664

Group type: EXPERIMENTAL
Intervention: Whole blood
Number of subjects: 2964

Group type: EXPERIMENTAL
Intervention: Red cell concentrates (RCC)
Number of subjects: 2964

Group type: EXPERIMENTAL
Intervention: Packed cells
Number of subjects: 2964

Group type: COMPARATOR
Intervention: Training intervention
Number of subjects: 2964

Group type: EXPERIMENTAL
Intervention: Storage duration
Number of subjects: 2964

Group type: COMPARATOR
Intervention: Initial audit
Number of subjects: 2964

Group type: COMPARATOR
Intervention: Third audit post-training
Number of subjects: 2964
Study: 30135830

Group type: EXPERIMENTAL
Intervention: Blended computer- and multimedia-supported psychoeducational group intervention
Number of subjects: 46
Study: 27695894

Group type: EXPERIMENTAL
Intervention: Nurse-led intensive care recovery program plus standard care
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Nurse-led intensive care recovery program
Number of subjects: 386

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 386
Study: 24422887

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 8 weeks
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Laboratory-based genomic studies
Number of subjects: 273
Study: 23019303

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 1000 mg i.m. injection followed by 500 mg injection every 6 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) + levonorgestrel (LNG) 250 μg orally daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Testosterone treatment in cynomolgus monkeys
Number of subjects: 36
Study: 19413375

Group type: EXPERIMENTAL
Intervention: Early headgear (HG) treatment
Number of subjects: 68

Group type: COMPARATOR
Intervention: Minor interceptive procedures
Number of subjects: 68
Study: 17349681

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg once daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone (88 microg, 2 puffs twice daily)
Number of subjects: 0
Study: 15072107

Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/day
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/day
Number of subjects: 613

Group type: COMPARATOR
Intervention: Carbamazepine (600 mg/day)
Number of subjects: 613

Group type: COMPARATOR
Intervention: Valproate (1250 mg/day)
Number of subjects: 613
Study: 11511432

Group type: EXPERIMENTAL
Intervention: Tezosentan (5, 20, 50, 100 mg h(−1))
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nitrate vasodilators or nesiritide
Number of subjects: 38
Study: 9062499

Group type: EXPERIMENTAL
Intervention: Once weekly T4 therapy (7 times the normal daily dose)
Number of subjects: 12
Study: 8164211

Group type: EXPERIMENTAL
Intervention: Adapted sphygmomanometer
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Vigorometer
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Penny & Giles myometer
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no low back pain)
Number of subjects: 33
Study: 3518556

Group type: EXPERIMENTAL
Intervention: 5 mg aerosolized verapamil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 12.5 mg aerosolized verapamil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30465488

Group type: EXPERIMENTAL
Intervention: Allied Health Leadership Development Program (n=16)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (n=17)
Number of subjects: 16
Study: 27567447

Group type: EXPERIMENTAL
Intervention: Single dose of stimulant medication
Number of subjects: 87
Study: 24794763

Group type: EXPERIMENTAL
Intervention: Arthrocentesis alone (n=17)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Arthrocentesis with triamcinolone hexacetonide (n=21)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 21
Study: 22932717

Group type: EXPERIMENTAL
Intervention: LCZ696 (200 mg twice daily)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Valsartan (160 mg twice daily)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: LCZ696
Number of subjects: 301

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 301
Study: 20695686

Group type: EXPERIMENTAL
Intervention: Oral caffeine (250 mg/70 kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 17968001

Group type: EXPERIMENTAL
Intervention: 1 drug administered at bedtime
Number of subjects: 250

Group type: COMPARATOR
Intervention: All drugs taken on awakening
Number of subjects: 250
Study: 16970086

Group type: EXPERIMENTAL
Intervention: Fuzheng Capsule (FC) and Quxie Capsule (QC)
Number of subjects: 101

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 101
Study: 12936975

Group type: COMPARATOR
Intervention: Single doses of posaconazole oral tablets (50 to 1200 mg)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Posaconazole oral tablets (50 to 400 mg) twice daily for 14 days
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Posaconazole (all doses)
Number of subjects: 103
Study: 10817713

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 295

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study: 9345411

Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 0
Study: 8508331

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control (no fish oil supplementation)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Visual assessment
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Quantitative computer analysis
Number of subjects: 151
Study: 3555042

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (750 mg twice daily)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Cefotaxime (2 g three times daily)
Number of subjects: 61
Study: 31840739

Group type: EXPERIMENTAL
Intervention: Counterargument invitation letters
Number of subjects: 6313

Group type: EXPERIMENTAL
Intervention: Sunk costs invitation letters
Number of subjects: 6313

Group type: COMPARATOR
Intervention: Control (standard invitation)
Number of subjects: 6313
Study: 29406427

Group type: EXPERIMENTAL
Intervention: AR-L (aerobic before low-intensity resistance training)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RA-L (aerobic after low-intensity resistance training)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AR-M (aerobic before moderate-intensity resistance training)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RA-M (aerobic after moderate-intensity resistance training)
Number of subjects: 60

Group type: COMPARATOR
Intervention: CON (nonintervention control)
Number of subjects: 60
Study: 27335220

Group type: EXPERIMENTAL
Intervention: 10 mg yohimbine
Number of subjects: 118

Group type: COMPARATOR
Intervention: 0.15 mg clonidine
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 118
Study: 24508328

Group type: EXPERIMENTAL
Intervention: Self-paced walking on a treadmill (TM)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Table tennis played continuously against the iPong robot (TT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rest (CON)
Number of subjects: 12
Study: 22267390

Group type: EXPERIMENTAL
Intervention: HIT (High-Intensity Interval Training) - 6 × 3-min at 90% Vo(2max) with recovery periods at 50% Vo(2max)
Number of subjects: 10

Group type: COMPARATOR
Intervention: CONT (Continuous Running) - 50-min continuous running at 70% Vo(2max)
Number of subjects: 10
Study: 19574172

Group type: EXPERIMENTAL
Intervention: Calcium carbonate 500 mg twice daily for 3 months
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 17319414

Group type: EXPERIMENTAL
Intervention: Squatting position (Group A)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Supine position (Group B)
Number of subjects: 200
Study: 15045505

Group type: EXPERIMENTAL
Intervention: Exhaustive exercise (unilateral biceps curls to exhaustion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shorter exercise period (unilateral biceps curls for 25% of the time to exhaustion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exhaustive exercise (unilateral biceps curls)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-exercising limb (after exhaustive exercise)
Number of subjects: 0
Study: 11560832

Group type: EXPERIMENTAL
Intervention: CT examinations for brain
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CT examinations for chest
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CT examinations for abdomen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CT examinations for pelvis
Number of subjects: 10
Study: 9484878

Group type: EXPERIMENTAL
Intervention: grepafloxacin 400 mg once daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: grepafloxacin 600 mg once daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: ciprofloxacin 500 mg bd
Number of subjects: 32

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study: 8049997

Group type: EXPERIMENTAL
Intervention: External beam radiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selected nonrandomized series
Number of subjects: 0
Study: 2455149

Group type: EXPERIMENTAL
Intervention: Captopril (50-100 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Verapamil (160-240 mg/day)
Number of subjects: 12
Study: 28988687

Group type: EXPERIMENTAL
Intervention: Orantinib (200 mg, twice per day)
Number of subjects: 889

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Orantinib
Number of subjects: 889
Study: 26646462

Group type: EXPERIMENTAL
Intervention: Goal-directed therapy group (n = 62)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Usual care group (n = 64)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Goal-directed therapy (meta-analysis)
Number of subjects: 126
Study: 25937837

Group type: EXPERIMENTAL
Intervention: 8.0 mg oral melatonin nightly for 10 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Matching placebo nightly for 10 weeks
Number of subjects: 39
Study: 23355492

Group type: EXPERIMENTAL
Intervention: Restorations with resin-composite and GIC lining
Number of subjects: 53

Group type: COMPARATOR
Intervention: Restorations with resin-composite without GIC lining
Number of subjects: 53
Study: 20124733

Group type: EXPERIMENTAL
Intervention: SCH530348 (20 or 40 mg loading dose followed by 1 mg/d or 2.5 mg/d for 60 days)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Standard-of-care (aspirin, ticlopidine, and heparin)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: SCH530348 plus standard-of-care
Number of subjects: 117

Group type: COMPARATOR
Intervention: Standard-of-care alone
Number of subjects: 117
Study: 19035150

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (blood glucose control at 4.4 to 6.1 mmol/L)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional group (blood glucose control at 10.0 to 11.1 mmol/L)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 46
Study: 17235728

Group type: EXPERIMENTAL
Intervention: ACE chemotherapy (doxorubicin 40 mg/m², cyclophosphamide 1000 mg/m², etoposide 120 mg/m² on day 1 IV, plus oral etoposide 240 mg/m² daily on days 2-3) with pegfilgrastim 6 mg by subcutaneous injection on day 4 of each cycle
Number of subjects: 30
Study: 14635368

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 203

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 203
Study: 10996578

Group type: EXPERIMENTAL
Intervention: Commercial program (Weight Watchers)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Self-help program
Number of subjects: 423
Study: 8851907

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (BIC) 0.3 g.kg body mass‐1
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Sodium citrate (CIT) 0.5 g.kg body mass‐1
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (PLC, wheat flour, 0.5 g.kg body mass‐1)
Number of subjects: 7
Study: 1340797

Group type: EXPERIMENTAL
Intervention: Continuous electronic foetal heart rate monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent monitoring using hand held doppler foetal heart rate detector
Number of subjects: 0
Study: 6650625

Group type: EXPERIMENTAL
Intervention: Nova-T
Number of subjects: 0

Group type: COMPARATOR
Intervention: Copper-T-200
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 0
Study: 31607279

Group type: EXPERIMENTAL
Intervention: HitnRun mobile game intervention
Number of subjects: 144

Group type: COMPARATOR
Intervention: Psychoeducational brochure
Number of subjects: 144
Study: 30580266

Group type: EXPERIMENTAL
Intervention: goserelin 3.6 mg/28 days by subcutaneous injection plus oral anastrozole 1 mg/day for 12 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: oral tamoxifen 20 mg/day for 12 weeks
Number of subjects: 12
Study: 26752186

Group type: EXPERIMENTAL
Intervention: Active participants in the P‐BRC
Number of subjects: 6344

Group type: COMPARATOR
Intervention: Inactive participants
Number of subjects: 6344
Study: 25175762

Group type: EXPERIMENTAL
Intervention: Purple grape juice (pGJ), 6 ounces twice daily for 4 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Clear apple juice (cAJ), 6 ounces twice daily for 4 weeks
Number of subjects: 24
Study: 22341377

Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise program (3 months, starting at 16 to 20 weeks of gestation)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual activities (control group)
Number of subjects: 80
Study: 20590748

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg od for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 40
Study: 17520238

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fenofibrate (FENO)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Addition of FENO to PIO
Number of subjects: 15

Group type: COMPARATOR
Intervention: Addition of PIO to FENO
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: FENO
Number of subjects: 15
Study: 16361631

Group type: EXPERIMENTAL
Intervention: Tailored decision support system (DSS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control arm (standard care)
Number of subjects: 32
Study: 12088161

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day, increased to a maximum of 60 mg/day after week 2)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 10438710

Group type: EXPERIMENTAL
Intervention: Protocol II (early reinduction treatment) for SRG patients
Number of subjects: 218

Group type: COMPARATOR
Intervention: No early reinduction treatment for SRG patients
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Protocol S (late intensification) for RG patients
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Overall treatment (DCLSG ALL-7)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: SRG patients receiving protocol II
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: RG patients
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: EG patients
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Overall CNS prophylaxis (systemic high-dose methotrexate and intrathecal chemotherapy)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Overall CNS relapse rate
Number of subjects: 218

Group type: COMPARATOR
Intervention: SRG patients not receiving protocol II
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 218
Study: 7489843

Group type: EXPERIMENTAL
Intervention: B10Asp
Number of subjects: 21

Group type: COMPARATOR
Intervention: Actrapid
Number of subjects: 21
Study: 2111126

Group type: EXPERIMENTAL
Intervention: Glucan (50 mg/m2, intravenously daily for 7 days)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (intravenously daily for 7 days)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Glucan
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38